A new oral treatment for chronic pain in irritable bowel syndrome
Official title: A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome
Funded at Fzata, INC. · NIH-10976389 · Data updated 2026-11-12
This study is testing a new oral treatment made from a special probiotic yeast that aims to help people with irritable bowel syndrome (IBS) by reducing chronic pain and improving their overall gut health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fzata, INC. NIH-funded |
| Lab location | 1 site (Halethorpe, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $2,091,549 |
| NIH project number | 1UG3NS135350-01A1 |
| Project ID | NIH-10976389 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with irritable bowel syndrome who experience chronic visceral pain.
✕Less likely to help
Patients with IBS who do not experience chronic visceral pain or those with other underlying gastrointestinal disorders may not benefit from this research.
What this research studies
This research investigates a novel oral biotherapeutic designed to alleviate chronic visceral pain associated with irritable bowel syndrome (IBS). The approach focuses on targeting tumor necrosis factor-alpha (TNF-α), a key inflammatory mediator linked to pain in IBS patients. By using an engineered probiotic yeast that produces a neutralizing antibody against TNF-α, the study aims to reduce pain and improve the quality of life for those suffering from this condition. Patients will be monitored for pain relief and overall gastrointestinal health during the treatment period.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from chronic pain due to irritable bowel syndrome.
How similar studies have gone: Previous research has shown promise in targeting TNF-α for pain management, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Fzata, INC.
Halethorpe, United States Active
Researchers
- Principal investigator: Yang, Zhiyong — Fzata, INC.
- Study coordinator: Yang, Zhiyong
Related research
Other NIH-funded projects on the same topics.
-
New oral therapy for IBS-related abdominal pain using a TNF-α–neutralizing probiotic
A new oral biotherapeutic pill made from a probiotic yeast targets gut inflammation to relieve chronic abdominal pain in people with irritable bowel syndrome.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.